ClinTec, in 2013 had its International launch, and enrolled students from fifteen countries into its innovative ‘Masters in International Clinical Research and Technology’ degree, an academic course run in conjunction with Edinburgh Napier University. Furthermore, the year has seen the company enhance its worldwide clinical operations, with a new office opening in Turkey, an expansion of operations in Russia and South Africa, as well as making further strides in the burgeoning Middle East and North Africa (MENA) market. Success was also marked by owner and founder, Dr. Rabinder Buttar, winning the accolade of ‘Female Entrepreneur of the Year’ at the 2013 Scottish Business Awards, the largest business awards ceremony in the UK and one attended by ex-US President, Bill Clinton.
Commenting on the news of ClinTec’s place on the final shortlist, and reflecting on her company’s achievements so far this year, Dr Buttar said; “I am delighted to see ClinTec International once again being named as a finalist at the SCRIP Awards. Indeed, to be placed in the category of Best CRO, alongside a prestigious array of other commercial organisations, highlights the industry recognition that we enjoy for all the clinical work that we carry out for pharma and biotech companies on a daily basis. We are proud to count all of the world’s top five pharma companies amongst our growing client list, and we hope to continue enjoying a tremendously fruitful working relationship with all of our clients the world over. 2013 has been another highly successful growth year for our company, with our clinical operations expanding into new countries and territories, and the rolling out of our MSc programme. I am confident that we will continue forward in a similar vein as we head into the final quarter.”
She added: “with the company scheduled to appear at the Outsourcing Clinical Trials Conferences in San Diego and Boston respectively at the end of the month, we are set to further build and increase our 2013 presence in the markets with strong exposure to international life science and pharmaceutical companies.”